Last reviewed · How we verify
Loteprednol etabonate suspension
At a glance
| Generic name | Loteprednol etabonate suspension |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection (PHASE4)
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (PHASE4)
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax (PHASE4)
- DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (PHASE4)
- The DEPOT Study (Dry Eye Prescription Options for Therapy) (PHASE4)
- Loteprednol vs. Prednisolone and Fluorometholone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol etabonate suspension CI brief — competitive landscape report
- Loteprednol etabonate suspension updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI